Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: Implications for future clinical trials

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 10, 2011, Pages 1340-1346

  Esfahani, K ^a,b   Aspler, A ^a,c   Menzies, D ^a,b,d   Schwartzman, Kevin J ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cost effectiveness; Decision analysis; Isoniazid; Latent infection; Rifampin; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CANADA; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); CONTACT EXAMINATION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; SENSITIVITY ANALYSIS; TREATMENT DURATION; TUBERCULIN TEST; UNSPECIFIED SIDE EFFECT;

ADULT; ANTITUBERCULAR AGENTS; BRAZIL; CANADA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MODELS, ECONOMIC; RESEARCH DESIGN; RIFAMPIN; SAUDI ARABIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053202396     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0575     Document Type: Article

References (35)

1. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49(RR-6): 1-51.
2. Long R. Canadian tuberculosis standards. 6th ed. Ottawa, ON, Canada: Canadian Lung Association & Public Health Agency of Canada, 2007.
3. Comstock G W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-850. (Pubitemid 29488035)
4. Page K R, Sifakis F, Montes de O R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166: 1863-1870. (Pubitemid 44455169)
5. Garibaldi R A, Drusin R E, Ferebee S H, Gregg M B. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972; 106: 357-365.
6. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman L B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130: 1712-1717. (Pubitemid 46033423)
7. Villarino M E, Ridzon R, Weismuller P C, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155: 1735-1738. (Pubitemid 27216686)
8. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992; 145: 36-41.
9. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697.
10. Nolan C M, Aitken M L, Elarth A M, Anderson K M, Miller W T. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis 1986; 133: 431-436. (Pubitemid 16126277)
11. Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. (Pubitemid 44564795)
12. National Cancer Center. Common terminology criteria for adverse events. Plainview, NY, USA: NCC, 2006. http://ctep. cancer.gov/protocolDevelopment/ electronic-applications/docs/ ctcaev3.pdf
13. Comstock G W, Baum C, Snider D E Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel Isoniazid Studies. Am Rev Respir Dis 1979; 119: 827-830.
14. Weinstein M C, Siegel J E, Gold M R, Kamlet M S, Russell L B. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-1258. (Pubitemid 26337709)
15. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and nontuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-1204. (Pubitemid 44713473)
16. Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle 1966; 47: 308.
17. Grzybowski S, Barnett G D, Styblo K. Contacts of cases of activepulmonary tuberculosis. Bull Int Union Tuberc 1975; 50(1): 90-106.
18. Ferebee S H, Mount F W, Murray F J, Livesay V T. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis 1963; 88: 161-175.
19. Nolan C M, Elarth A M. Tuberculosis in a cohort of Southeast Asian refugees. A five-year surveillance study. Am Rev Respir Dis 1988; 137: 805-809. (Pubitemid 18099289)
20. Wright A, Zignol M. Anti-tuberculosis drug resistance in the world: fourth global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: World Health Organization, 2008.
21. Salpeter S R, Sanders G D, Salpeter E E, Owens D K. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127: 1051-1061. (Pubitemid 28012074)
22. Ormerod L P, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tubercle Lung Dis 1996; 77: 37-42. (Pubitemid 26066608)
23. Aspler A, Long R, Trajman A, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010; 65: 582-587.
24. Menzies D, Oxlade O, Lewis M. Costs for tuberculosis care in Canada. Ottawa, ON, Canada: Public Health Agency of Canada, 2006. http://www.phac-aspc. gc.ca/tbpc-latb/costtb/pdf/ cost-tb-e.pdf Accessed July 2011.
25. Commission des Normes de Travail du Quebec. History of the minimum wage. Montreal, QC, Canada: Government of Quebec, 2011. http://www.cnt.gouv.qc.ca/en/ wages-pay-and-work/ wages/history-of-the-minimum-wage/index.html Accessed July 2011.
26. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161(3 Pt 1): 780-789. (Pubitemid 30171731)
27. Public Health Agency of Canada. Tuberculosis in Canada. Ottawa, ON, Canada: Public Health Agency of Canada, 2004. http://www.phac-aspc.gc.ca/ publicat/2007/tbcan04/pdf/ tbcan04-e.pdf Accessed July 2011.
28. Statistics Canada. Life table for the first year of life, Canada, 2000 to 2002. Ottawa, ON, Canada: Statistics Canada, 2009. http://www.statcan.gc.ca/ pub/84-537-x/4064441-eng.htm Accessed July 2011.
29. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
30. Blackwelder W C. 'Proving the null hypothesis' in clinical trials. Controlled Clin Trials 1982; 3: 345-353. (Pubitemid 13113168)
31. Ryan P. Sample size for equivalence trials in STATA. College Station, TX, USA: Stata Corp, 2011. http://www.stata.com/ statalist/archive/2003-02/ msg00212.html Accessed July 2011.
32. Menzies D. A randomized clinical trial comparing 4RMP vs. 9INH for treatment for latent tuberculosis infection (LTBI). Part 3: effectiveness. Bethesda, MD, USA: US National Institutes of Health, 2011. http:/clinicaltrials. gov/ct2/show/NCT00931736 Accessed July 2011.
33. Holland D P, Sanders G D, Hamilton C D, Stout J E. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009; 179: 1055-1060.
34. Dion M J, Tousignant P, Bourbeau J, Menzies D, Schwartzman K. Measurement of health preferences among patients with tuberculous infection and disease. Med Decis Making 2002; 22 (Suppl): S102-S114.
35. Guo N, Marra C A, Marra F, Moadebi S, Elwood R K, Fitzgerald J M. Health state utilities in latent and active tuberculosis. Value Health 2008; 11: 1154-1161.